Katie S. Murray

Dr. Katie S. Murray


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2023 in Translational Andrology and Urology
Verified
Journal Article
Open access
PDF file
JGJosh Gottlieb
Josh Gottlieb
JLJennifer Linehan
Jennifer Linehan
KMKatie S. Murray
Katie S. Murray
Localized upper tract urothelial carcinoma (UTUC) is a difficult disease for clinicians to treat, due to the multitude of oncological and patient factors to consider. Despite the challenges of diagnostic staging, endoscopic management, and disease recurrence, there is still a need for local therapeutic options that do not subject patients to the morbidities of radical nephroureterectomy (RNU). Intraluminal chemotherapies have allowed for improved oncological control in patients with low-grade disease receiving renal-sparing treatment approaches. This narrative review discusses the treatment modalities available for localized low-grade UTUC, with a focus on the current status of chemoablation. The OLYMPUS trial was a pivotal study that lead to the Food and Drug Administration (FDA) approval of UGN-101 (mitomycin-C) in April 2020 for the treatment of low-grade UTUC, and intraluminal chemotherapy is now a widely used modality for managing this disease. The trial reported a complete response (CR) rate of 59%, and an estimated treatment durability of 82% at 1 year. However, a concern was the reported 44% ureteral stricture rate using the retrograde approach. More research is currently underway to determine the ideal instillation method for intraluminal therapies (e.g., retrograde vs. antegrade). Lastly, we discuss upcoming treatment options. Newer novel agents like padeliporfin vascular targeted photodynamic (VTP) therapy (brand name TOOKAD) are currently being studied, which will in hope provide additional treatment options for UTUC patients.

3 October 2025 in Cancers
Verified
Journal Article
Open access
PDF file
SCSamuel Carbunaru
Samuel Carbunaru
JRJordan Rich
Jordan Rich
KMKatie S. Murray
Katie S. Murray
Upper tract urothelial carcinoma (UTUC) is a rare malignancy that accounts for a small minority of all urothelial cancers. Historically, treatment recommendations for UTUC have been extrapolated from bladder cancer trials due to limited high-quality, UTUC-specific evidence. However, emerging data has shown how UTUC exhibits distinct biological, molecular, and clinical features compared to bladder cancer. In this piece, we provide an analysis of the current evidence supporting adjuvant chemotherapy and immunotherapy for UTUC. We discuss landmark trials such as the POUT trial for adjuvant chemotherapy, as well as pivotal trials such as CheckMate 274, IMvigor 010 and AMBASSADOR that examine the role of adjuvant immunotherapy for UTUC. Additionally, we briefly highlight advances in cancer genetics and the emerging use of circulating tumor DNA as a potential biomarker. While there has been significant progress made in adjuvant treatments for UTUC, substantial knowledge gaps remain. Clinical trials using UTUC-specific populations will be critical in improving outcomes and personalizing care for this patient population.

1 April 2025 in Cancers
Verified
Journal Article
Open access
PDF file
MRMitesh Rajpurohit
Mitesh Rajpurohit
MGMojgan Golzy
Mojgan Golzy
CCChen Chen
Chen Chen
KMKatie S. Murray
Katie S. Murray
GRGeoffrey Rosen
Geoffrey Rosen
Background: The relationship between body composition and bladder cancer outcomes is complex. While a higher body mass index (BMI) has been associated with an increased risk of bladder cancer development, its impact on survival outcomes is less clear. This study aimed to explore the association between BMI, survival, health-related quality of life, and the performance of ADLs in a cohort of older patients with bladder cancer. Methods: Data were obtained from the Surveillance, Epidemiology, and End Results-Medicare Health Outcomes Survey, including patients diagnosed with bladder cancer who had recorded BMI values. Analysis of variance was used to assess the association between BMI categories and patient demographics as well as cancer/treatment characteristics. Generalized linear models examined the impact of BMI on health-related quality of life, as measured by the physical and mental component summary scores when controlling for confounding variables. Kaplan–Meier survival curves across BMI categories were compared using log-rank tests. Results: The final cohort consisted of 8013 patients (age ≥ 65) with a mean age of 77.7 ± 7.1 years, the majority of whom were White (85.6%) and male (74.8%). We observed no significant association between BMI and cancer/treatment characteristics. The severely obese subgroup had the highest rate of disability in performing ADLs (18.3%) followed by the underweight subgroup (10.3%). Overweight patients exhibited the highest physical and mental component summary scores, indicating better health-related quality of life. BMI was a significant predictor of overall survival, with overweight, obese, and severely obese patients demonstrating improved survival compared to those with healthy or underweight BMI. These findings remained statistically significant in multivariable analysis. Conclusions: Our findings suggest a dual role of BMI in older patients with bladder cancer: higher BMI provides a survival advantage and, to an extent, a QoL advantage. At the same time, severe obesity did lead to the lowest QoL despite improved survival outcomes. These results underscore the complex interplay between BMI, survival, and QoL in this bladder cancer population.

1 November 2023 in JU Open Plus
Verified
Journal Article
Open access
JPJesse Persily
Jesse Persily
KMKatie S. Murray
Katie S. Murray

29 November 2025 in Cancers
Verified
Journal Article
Open access
PDF file
JPJesse Benjamin Persily
Jesse Benjamin Persily
SWSimon White
Simon White
KMKatie S. Murray
Katie S. Murray
Despite the advent and growth of endoscopic and nephron-sparing management approaches, the mainstay treatment for upper tract urothelial carcinoma (UTUC) in 2025 remains radical nephroureterectomy (RNU). Classic teaching, largely derived from the benefit seen in the muscle-invasive bladder cancer (MIBC) population, supports the inclusion of retroperitoneal lymph node dissection (LND), particularly for high-risk and high-grade disease. However, no level 1 evidence exists supporting the inclusion of an LND at the time of extirpative surgery for UTUC. Moreover, studies attempting to map lymph node dissection relative to primary UTUC tumor location are plagued by limitations. Herein, we summarize and review available data regarding proposed LND templates for the management of UTUC.